GT Biopharma Inc
gtbiopharma.comWhat Do They Do?
Develops immune-based drug candidates that direct patients’ natural killer cells toward cancer cells, with candidates aimed at blood cancers and solid tumors.
10-K for FY2025, filed Mar 2, 2026We are a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products based…View ↗
GTB-3650 is a TriKE® which targets CD33 on the surface of myeloid leukemias and an agonistic camelid engager to the potent activating…View ↗
GTB-5550 is a B7-H3 targeted TriKE® which targets B7-H3 on the surface of advanced solid tumors (figure above). GTB-5550 is our first dual…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$4.5MView ↗
- ▼ −85% (Loss)
- vs −$30.2M in Q2 FY2025
-
May 22, 2026
Nasdaq grants more time to regain minimum bid-price compliance
The additional compliance period runs through November 16, 2026.
Sources
8-K, filed May 22, 2026
On May 20, 2026, GT Biopharma, Inc., a Delaware corporation (the “Company”), received a letter from the Nasdaq Listing Qualifications Staff…View ↗
Additional engager platform
The latest report describes an additional fusion-protein engager platform alongside the TriKE platform described in the older report.
10-K for FY2022, filed Mar 30, 2023 10-K for FY2025, filed Mar 2, 2026We are a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products based…View ↗
We are a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products based…View ↗
Autoimmune disease candidate
The latest report adds a candidate aimed at lupus and other autoimmune disorders to the platform’s stated disease uses.
10-K for FY2022, filed Mar 30, 2023 10-K for FY2025, filed Mar 2, 2026We are using our TriKE® platform with the intent to bring to market immuno-oncology products that can treat a range of hematologic…View ↗
GTB-7550 TriKE® is a product candidate in development for the treatment of lupus and other autoimmune disorders. GTB-7550 TriKE® is a…View ↗
Loading...
